The global membrane chromatography market is on a steep growth trajectory as biopharmaceutical manufacturers increasingly turn to this purification technique to meet surging demand for proteins, antibodies, and nucleic acid-based therapeutics. Market analysis places the sector’s 2023 valuation at approximately USD 296.4 million, with projections indicating growth from USD 336.0 million in 2024 to nearly USD 865.0 million by 2031 — a compound annual growth rate of 14.46% across the forecast period, among the strongest expansion rates within the broader bioprocessing equipment landscape.
Why Membrane Chromatography Is Gaining Ground
Membrane chromatography represents a distinct departure from traditional resin-based column chromatography, instead utilizing specialized membrane surfaces to facilitate the adsorption and purification of target biomolecules. This structural difference translates into tangible operational advantages: higher throughput, reduced processing times, and lower overall costs, particularly for large-scale and continuous bioprocessing applications. As biopharmaceutical production scales up globally to meet growing therapeutic demand, these efficiency gains have become increasingly difficult for manufacturers to ignore.
The technology plays a particularly critical role in downstream purification steps, including the capture of large particles such as viruses and viral vectors, as well as polishing processes designed to eliminate residual DNA, host cell proteins, and other contaminants. Heightened regulatory scrutiny around downstream purification validation has only reinforced the importance of reliable, high-performance chromatography solutions within modern biomanufacturing workflows.
Investment and R&D Momentum
Research and development spending across the broader biopharmaceutical sector provides important context for this market’s growth. According to the International Federation of Pharmaceutical Manufacturers & Associations, global biopharmaceutical R&D expenditure was projected to exceed USD 202 billion in 2024, a figure that significantly outpaces R&D investment in industries such as aerospace, defense, chemicals, and software services. This scale of investment directly fuels demand for advanced purification technologies capable of supporting increasingly complex biologic therapies moving through development pipelines.
Regulatory approval trends further reinforce this dynamic. Data from the U.S. Center for Drug Evaluation and Research indicates that approximately 55 new drugs received approval in 2023, representing nearly a 50% increase compared to the prior year. As the volume and complexity of approved biologics continues to expand, so too does the need for purification technologies capable of handling increasingly sophisticated and sensitive biomolecules at commercial scale.
Strategic Moves Reshaping the Competitive Field
Consolidation and collaboration have become defining features of the competitive landscape. Donaldson Company’s 2022 acquisition of Purilogics — a biotechnology firm specializing in membrane chromatography solutions for purifying mRNA, monoclonal antibodies, and other proteins — significantly enhanced Donaldson’s capacity to serve escalating demand for advanced bioprocessing technologies. More recently, Ecolab partnered with Repligen Corporation to introduce DurA Cycle, a new protein A chromatography resin engineered specifically for large-scale biopharmaceutical purification, extending an existing collaborative relationship between Purolite and Repligen.
Other players are pursuing innovation through product development and academic partnership. Tosoh Bioscience launched its Octave BIO Multi-Column Chromatography system alongside complementary pre-packed columns in 2022, aimed at accelerating pre-clinical process development. Shimadzu, meanwhile, collaborated with the University Medical Center Göttingen in Germany to advance liquid chromatography-mass spectrometry techniques for therapeutic drug monitoring — an example of how academic-industry partnerships continue to push analytical capabilities forward within the sector.
Segmentation Insights
By type, ion exchange membrane chromatography led the market in 2023 with revenue of approximately USD 149.2 million, and is expected to retain its leadership position through 2031 with projected revenue of USD 439.3 million. This segment’s dominance stems from its broad applicability in antibody polishing and virus purification, where its scalability, disposability, high throughput, and reduced buffer consumption offer clear operational advantages over alternative purification methods.
Operation mode analysis shows the flow-through segment capturing the largest market share in 2023, at approximately 61.56%. This method enables continuous biopharmaceutical processing with meaningfully reduced processing times compared to traditional batch approaches, an advantage that continues to gain regulatory recognition as manufacturers prioritize both efficiency and consistent product quality.
End-user segmentation reveals pharmaceutical and biopharmaceutical companies as the dominant demand source, with projected revenue reaching USD 476.8 million by 2031. These organizations continue to expand R&D investment aimed at new drug discovery, while simultaneously pursuing global market expansion strategies that require robust, compliant purification infrastructure capable of meeting varied international regulatory standards.
Regional Trends
North America currently leads global market share, accounting for approximately 35.76% in 2023 with a valuation of USD 106.0 million. The region’s dominance reflects the concentration of major pharmaceutical company headquarters and research facilities within the United States. According to the U.S. Department of Health and Human Services, approximately 15,316 clinical trials involving biopharmaceuticals were registered domestically in 2022 alone — a figure that highlights the sheer scale of drug development activity driving regional demand for advanced purification technologies across therapeutic areas including oncology, cardiovascular disease, and diabetes.
Europe is projected to be the fastest-growing region, with an anticipated CAGR of 14.91% through 2031. The presence of numerous prominent pharmaceutical companies and research institutions across the continent continues to drive demand for cutting-edge chromatography technologies, supported by substantial R&D investment aimed at improving biopharmaceutical efficacy and safety profiles. With a robust volume of clinical trials registered annually, Europe remains a key global hub for advancing therapies targeting oncology, cardiovascular conditions, and other chronic diseases.
Addressing Manufacturing Complexity
Even amid this strong growth outlook, the market faces meaningful technical challenges rooted in the inherent complexity and variability of biopharmaceutical production. Biologics such as monoclonal antibodies and viral vectors demand highly precise purification methods capable of handling diverse and often delicate biomolecules, and maintaining consistent performance across varying production scales remains technically demanding.
Leading manufacturers are addressing this complexity through sustained R&D investment focused on advancing membrane materials and chromatography system design, aimed at improving both purification efficiency and scalability across a widening range of biopharmaceutical applications. Strategic acquisitions and portfolio expansion continue to serve as key mechanisms through which established players strengthen their competitive positioning while navigating these manufacturing complexities.
Looking Forward
With companies including Danaher, Merck KGaA, Sartorius, Thermo Fisher Scientific, 3M, Donaldson, Restek, Agilent Technologies, Bio-Rad Laboratories, and Shimadzu continuing to invest heavily in innovation, the membrane chromatography market appears poised for sustained double-digit growth through the remainder of the decade. As biopharmaceutical pipelines grow increasingly complex and global regulatory scrutiny around purification validation intensifies, membrane chromatography’s efficiency and scalability advantages position it as an increasingly indispensable technology within modern biomanufacturing.
